1
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiother 2018; 22:222-228. [PMID: 29650388 DOI: 10.1016/j.canrad.2017.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 10/04/2017] [Indexed: 10/17/2022]
Abstract
PURPOSE To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. MATERIAL AND METHODS This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at 12 and 36 months after its completion. The study was designed to evaluate the toxicity at one year, 3 years and 5 years. RESULTS Sixty-four patients were included from October 2007 to August 2010. All of them received concurrent adjuvant radiotherapy and bevacizumab (in 24 cases after primary systemic treatment). All patients received non-fractionated radiotherapy to breast or chest wall with or without irradiation of regional lymph nodes. Early toxicity has been previously reported. Median follow-up was 46.4 months (range: 18-77 months). Median age was 53 years old (range: 23-68 years). The 3-years overall survival was 93% (range: 87-100%). Evaluation of the toxicity at 3 years was available for 67% of the patients. There was a low rate of toxicity: 14% grade 1 pain, 9% grade 1 fibrosis, 2% grade 1 telangiectasia, 2% grade 1 paresis, 7% grade 1 lymphedema and 2% grade 3 lymphedema. No grade 4 toxicity was observed. No patient had a left ventricular ejection fraction below 50% at 3 years. CONCLUSIONS Concurrent bevacizumab with locoregional radiotherapy is associated with acceptable 3-years toxicity in patients with breast cancer.
Collapse
Affiliation(s)
- A Dautruche
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | - L Belin
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Cottu
- Oncology department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Bontemps
- Radiotherapy department, CHU Jean-Minjoz, 25030 Besançon, France
| | - C Lemanski
- Radiotherapy department, institut régional du cancer de Montpellier, 34298 Montpellier, France
| | - B de la Lande
- Radiotherapy department, institut Curie, René-Huguenin hospital, 92210 Saint-Cloud, France
| | - P Baumann
- Radiotherapy department, centre d'oncologie de Gentilly, 54000 Nancy, France
| | - F Missohou
- Radiotherapy department, centre Henri-Becquerel, 76038 Rouen, France
| | - C Lévy
- Radiotherapy department, centre François-Baclesse, 14000 Caen, France
| | - K Peignaux
- Radiotherapy department, centre Georges-François-Leclerc, 21079 Dijon, France
| | | | - F Denis
- Radiotherapy department, centre Jean-Bernard, 72000 Le Mans, France
| | - A Gobillion
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - V Pernin
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - Y Kirova
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| |
Collapse
|
2
|
Ajgal Z, de Percin S, Diéras V, Pierga J, Campana F, Fourquet A, Kirova Y. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity. Cancer Radiother 2017; 21:114-118. [DOI: 10.1016/j.canrad.2016.10.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 08/03/2016] [Accepted: 10/14/2016] [Indexed: 11/25/2022]
|
3
|
Kirova YM, Fourquet A. Concurrent Use of Radiation Therapy and Targeted Molecules in the Breast Cancer Treatment. Breast Cancer 2017. [DOI: 10.1007/978-3-319-48848-6_54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Noguchi M, Nakano Y, Noguchi M, Ohno Y, Kosaka T. Local therapy and survival in breast cancer with distant metastases. J Surg Oncol 2011; 105:104-10. [DOI: 10.1002/jso.22056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2011] [Accepted: 07/18/2011] [Indexed: 11/08/2022]
|